Aldosterone Contribution to Leptin-mediated Hypertension in Obese Females

Information

  • Research Project
  • 9199106
  • ApplicationId
    9199106
  • Core Project Number
    R01HL130301
  • Full Project Number
    5R01HL130301-02
  • Serial Number
    130301
  • FOA Number
    PA-13-302
  • Sub Project Id
  • Project Start Date
    1/1/2016 - 8 years ago
  • Project End Date
    12/31/2020 - 3 years ago
  • Program Officer Name
    MARIC-BILKAN, CHRISTINE
  • Budget Start Date
    1/1/2017 - 7 years ago
  • Budget End Date
    12/31/2017 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    02
  • Suffix
  • Award Notice Date
    12/23/2016 - 7 years ago

Aldosterone Contribution to Leptin-mediated Hypertension in Obese Females

? DESCRIPTION (provided by applicant): The recent obesity epidemic, which affects more women than men worldwide, is a major risk factor for hypertension and the cause of a three-fold increase in the prevalence of hypertension in young adult women. Despite decade of research investigating the mechanisms regulating blood pressure, millions of women remain inadequately treated for hypertension largely due to a lack of understanding of the sex-specificity of the mechanisms regulating blood pressure. In preliminary studies for this proposal, we have made major observations that shed significant new light on this issue. The first is that obesity-induced hypertension in females progresses differently from males and involves leptin-mediated increases in plasma aldosterone. Blockade of aldosterone disproportionately lowers blood pressure in obese female mice versus males. The second observation is the potential identification of novel site and regulator of aldosterone secretion. Human, rodent, and cell evidence indicate that leptin exerts a direct control of aldosterone secretion in adrenal glands and adipose tissue. The last observation is that leptin-induced aldosterone secretion is potentiated in females, by the presence of estrogen. Indeed, estrogen removal with ovariectomy abolishes the correlation between leptin and aldosterone. In the current proposal, we will rigorously test these concepts in three aims. The first aim will combine the use of pathophysiological models of obesity with a novel leptin receptor antagonist to identify the mechanisms regulating blood pressure in obese female mice. The second aim will employ pharmacological and cellular approach to determine the role of estrogen in leptin-mediated aldosterone secretion. The third aim will purse these concepts, in vivo, testing whether estrogen removal abolishes the aldosterone dependence of the mechanisms regulating blood pressure in obese female mice. Taken together these studies will provide new information on the sex-specificity of the mechanisms regulating blood pressure and will likely identify a new signaling pathway leading to the synthesis of aldosterone. Successful completion of these aims may identify new therapeutic strategies for obesity-related hypertension in women and provide the proof of principle required for sex-based clinical trials of therapeutic strategies to treat obesit-induced hypertension.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    130000
  • Total Cost
    380000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:380000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HM
  • Study Section Name
    Hypertension and Microcirculation Study Section
  • Organization Name
    GEORGIA REGENTS UNIVERSITY
  • Organization Department
    PHYSIOLOGY
  • Organization DUNS
    809593387; 966668691
  • Organization City
    AUGUSTA
  • Organization State
    GA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    309120004
  • Organization District
    UNITED STATES